img

News Topical, Digital Desk : There's good news for those suffering from obesity. Novo Nordisk launched its popular weight loss drug, Ozempic, in India on Friday. This drug is considered very effective for weight loss. 

Now, the launch of this drug in India could be a welcome relief for those suffering from obesity. Let's find out the price and dosage of this drug in India.

What is the price of this medicine?

Ozempic starts at ₹8,800 per month (four weeks). This drug is primarily for type 2 diabetes patients whose blood sugar levels are poorly controlled.

What is the speciality of this medicine?

Ozempic is based on a compound called semaglutide and is administered as a once-weekly injection. It is available in three dosages: 0.25mg, 0.5mg, and 1mg, depending on the individual's health condition, after consulting a doctor. The medication comes in a pre-filled pen, making injection easier and less painful.

Prices for the 0.25mg dose are ₹8,800, the 0.5mg dose is ₹10,170, and the 1mg dose is ₹11,175. Each pen contains a four-week dosage.

How does the medicine work?

Ozempic is a GLP-1 receptor agonist, which increases insulin production. Therefore, this drug is used to control type 2 diabetes. However, it also acts on the parts of the brain that control appetite, reducing food cravings. This also helps with weight loss and reduces the risk of heart and kidney problems associated with diabetes. Therefore, it is now being used as a weight loss drug. 

Recognition was received in 2017

Ozempic was approved by the US FDA in 2017 for type 2 diabetes, but its appetite-suppressing effects have also led to its widespread use for weight loss. However, in India, it has been launched solely as a diabetes medication. 

While diabetes and obesity are on the rise in India, the launch of this drug could prove helpful to many. However, the price of this drug is still quite high for many, making it difficult to afford. 


Read More: Preterm Birth Causes: Why are premature births on the rise in India? Learn the real reason behind premature delivery.

--Advertisement--